North America Cell Line Development Market size surpassed USD 1.4 billion in 2020 and is expected to witness 11% CAGR from 2021 to 2027. Growing demand of cell therapy in cancer treatment will boost the market expansion.
Get more details on this report - Request Free Sample PDF
Advancement in micro robotics, single cell dispensaries, flow cytometry had significant impact on the cell line development market revenue. Flow cytometry has gradually impacted on cell line development, as it increases the work efficiency during research work. Cell line development is very time-consuming work, at every single stage researcher faces limitations and challenges. From last few years, researcher have been developing advanced tools and strategies to reduce the challenges, especially for complex biologics such as DTE proteins.
Equipment segment is set to garner more than 11% growth rate through 2027. Numerous cell line development applications such as drug screening, biologics production is fueling the market demand. Centrifuge, and incubators are some of the main equipment playing important part in cell line culture. Cell line culture requires specific & strictly controlled environment. Specially designed incubators provide optimum growth conditions to cell culture such as humidity, temperature and CO2.
Mammalian source segment held over 71% North America cell line development market share in 2020. Chinese hamster ovary cells are commonly used mammalian cell. Most of the mammalian cells such as HEK293, HT-1080, and NS0 among others are used for therapeutic and recombinant protein production in large proportion.
Get more details on this report - Request Free Sample PDF
Hybridoma cell line segment will observe over 10% growth rate during the forecast period. Hybridoma technology is a technique that is used to generate monoclonal antibodies. Hybridoma cell line are used in applications such as production of monoclonal antibody, immunoglobin, and others. It is helpful in research work and development of assay. Improving focus on production of monoclonal antibodies will fuel the segment growth.
Bioproduction application segment value was around USD 658 million in 2020. Pharmaceutical industries focus on the development of therapeutic drugs including vaccines, cell therapies, protein-based therapies. Increasing number of biosimilars and biologic products will fuel the market demand with high productivity.
The U.S. cell line development market revenue is poised to expand at 11.4% CAGR till 2027. Rising adoption of novel technology, development of tools and techniques in research, growing demand of gene therapy in the U.S will drive the market size in the country.
Major players operating in the market are WuXi AppTec, Sartorius, Selexis, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Lonza Group, GE Healthcare, Corning Inc., GVK BIO, and Vista Biologicals. Companies focusing on research and development work, also production of novel product to gain more competitive advantage in the industry.